Loading...
•
Mar 31, 2023
Integra LifeSciences Q1 2023 Earnings Report
Integra LifeSciences' first quarter performance reflected revenue growth and reaffirmed financial guidance for the year.
Key Takeaways
Integra LifeSciences reported a 1.1% increase in first-quarter revenue to $380.8 million, with organic growth of 4.6%. The company reaffirmed its full-year 2023 revenue guidance of $1,602 million to $1,620 million and adjusted EPS guidance of $3.43 to $3.51.
First quarter revenues reached $380.8 million, a 1.1% increase on a reported basis and a 4.6% increase on an organic basis compared to the previous year.
GAAP earnings per diluted share were $0.29, while adjusted earnings per diluted share were $0.74, consistent with the prior year.
The company reaffirmed its full-year 2023 revenue and adjusted earnings per share guidance, projecting revenues between $1,602 million and $1,620 million and adjusted EPS between $3.43 and $3.51.
Integra is hosting its Investor Day on May 4, 2023, in New York, with a live webcast available on the company's website.
Forward Guidance
The Company is reaffirming its full-year 2023 revenue and adjusted EPS expectations of $1,602 to $1,620 million and $3.43 to $3.51, respectively. For the second quarter 2023, the Company expects reported revenues in the range of $396 million to $400 million, representing reported growth of -0.5% to 0.5% and organic growth of 1.5% to 2.5%. Adjusted earnings per diluted share are expected to be in the range of $0.75 to $0.79.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...